Cardurion is a clinical-stage cardiovascular biotechnology company developing new therapeutics for the treatment of heart failure and cardiovascular diseases. Cardurion’s product pipeline includes our lead clinical asset, CRD-733, a PDE-9 inhibitor with the potential to improve cardiac function in heart failure patients. Cardurion has an exclusive licensing agreement with Astellas for the development and commercialization of CRD-733. Additionally, Cardurion has a strong cardiovascular development partnership with Takeda which is fueling drug discovery and preclinical development work being conducted in our internal research laboratories.
Member count: 11-50
Founded date: 2017
Investors 2
| Date | Name | Website |
| 29.10.2021 | Bain Capit... | baincapita... |
| - | Bain Capit... | baincapita... |
Mentions in press and media 2
| Date | Title | Description | Category | Author | Source |
| 28.10.2021 | Robinhood’... | This is the web version of Ter... | - | - | fortune.co... |
| 28.10.2021 | Robinhood’... | This is the web version of Ter... | - | - | fortune.co... |